Best Telehealth Clinics in Louisiana (2026)

Louisiana's telehealth framework is governed by La. R.S. 40:1223.1 through 40:1223.6 (the Louisiana Telehealth Access Act). The state requires an in-person evaluation before prescribing controlled substances via telehealth under R.S. 40:1223.4. This in-person requirement applies to all scheduled drugs, including testosterone (Schedule III).

R.S. 40:1223.4(C) states that a practitioner may not prescribe a controlled substance through telehealth unless "the practitioner or another practitioner in the same group practice has performed at least one in-person medical evaluation of the patient." This means the in-person visit can be performed by a colleague in the same practice, not necessarily the prescribing provider. Telehealth platforms that operate group practices with local clinicians can satisfy this requirement.

The Louisiana Board of Pharmacy issued a notable enforcement action in April 2023, effectively banning the shipment of compounded semaglutide into Louisiana from out-of-state pharmacies. The board's position is that out-of-state pharmacies shipping compounded medications to Louisiana patients must hold a Louisiana non-resident pharmacy permit, and that compounded GLP-1s specifically face heightened scrutiny. This has disrupted supply chains for several national telehealth GLP-1 providers.

Louisiana is an active IMLC member. Out-of-state physicians can obtain expedited Louisiana licensure through the compact, but IMLC licensure does not waive the in-person controlled substance requirement under R.S. 40:1223.4.

HB 498 (2024) expanded Medicaid telehealth coverage parity and made several COVID-era expansions permanent, including audio-only coverage for behavioral health. Louisiana Medicaid covers GLP-1 receptor agonists for diabetes. Coverage for obesity indications is limited and requires prior authorization with strict criteria.

The Louisiana PDMP (PMP AWARxE) is mandatory under La. R.S. 40:1024. Providers must check the PDMP before prescribing Schedule II through V controlled substances. Louisiana also requires electronic prescribing for Schedule II substances and has moved toward mandatory EPCS for all schedules.

Louisiana has collaborative practice requirements for APRNs. Nurse practitioners must operate under a collaborative practice agreement with a physician for prescribing controlled substances. Louisiana is not a full practice authority state, which limits NP-staffed telehealth platforms.

Louisiana has 4.6 million residents. Provider availability for TRT is reduced due to the in-person requirement under R.S. 40:1223.4 and the APRN collaborative practice restriction. GLP-1 availability is further complicated by the Board of Pharmacy's compounded semaglutide shipping enforcement.

All-50-state providers like Maximus ($100/mo) and Hone Health ($25/mo) list Louisiana. These platforms presumably have group practice arrangements or local clinicians to satisfy the in-person requirement. TRT Nation ($99/mo, 45 states) includes LA. BraverX ($129/mo), PeterMD ($99/mo), and DudeMeds ($77/mo) list "Most US states" — verify Louisiana coverage directly.

GLP-1 availability is affected by the Board of Pharmacy's compounded semaglutide enforcement. Providers shipping compounded GLP-1s from out-of-state pharmacies without Louisiana non-resident permits face supply disruptions. National providers like Embody, SkinnyRx, DirectMeds, Zealthy, and Sesame Care serve Louisiana, but patients should confirm that the dispensing pharmacy holds a valid Louisiana permit.

HRT, hair loss, and ED providers with national coverage generally serve Louisiana. Midi Health accepts insurance. The APRN collaborative practice requirement does not affect physician-staffed platforms.

Enhance MD excludes Louisiana from its service area, consistent with the state's in-person requirement and APRN restrictions.

TRT pricing from available providers: DudeMeds $77/mo ($1,124/year), TRT Nation $99/mo ($1,446/year), PeterMD $99/mo ($1,188/year), Maximus $100/mo ($1,300/year), BraverX $129/mo ($1,548/year), Defy Medical $200/mo ($2,800/year). The in-person visit requirement adds $150 to $400 in indirect costs for the initial evaluation.

GLP-1 ranges from $99/mo to $399/mo. Median is $179/mo. Louisiana Medicaid covers GLP-1s for diabetes but has limited obesity coverage with strict PA criteria. The Board of Pharmacy's enforcement on compounded semaglutide may reduce the availability of lower-cost compounded options in Louisiana.

Louisiana does not tax prescription medications. The state sales tax is 4.45% (plus local taxes up to 7% combined in some parishes) but Rx drugs are exempt. Louisiana has a progressive income tax with rates from 1.85% to 4.25%.

HRT: Midi Health (insurance), PlushCare ($20/mo), Evernow ($35/mo). ED: Hims $17/mo to MEDVi $119/mo.

Louisiana's cost of living is below the national average, but the in-person visit requirement and pharmacy enforcement create additional costs and friction not present in more permissive states.

TRT (testosterone replacement therapy)

Louisiana requires an in-person evaluation before telehealth controlled substance prescribing under R.S. 40:1223.4. The evaluation can be performed by another practitioner in the same group practice. The federal DEA waiver through December 2026 provides federal authority, but the state in-person requirement adds a compliance layer. PDMP check required. NPs must operate under collaborative practice agreements. Both compounded and FDA-approved testosterone are available.

GLP-1 weight loss

The Board of Pharmacy's April 2023 enforcement action restricts out-of-state pharmacies from shipping compounded semaglutide into Louisiana without a non-resident pharmacy permit. Federal FDA compounding rules also apply. Louisiana Medicaid covers GLP-1s primarily for diabetes, with limited obesity coverage. Patients should verify that their telehealth provider's dispensing pharmacy has a valid Louisiana permit.

HRT (hormone replacement therapy)

HRT follows standard federal prescribing rules in Louisiana. Non-controlled HRT medications are not subject to the in-person requirement. No additional state restrictions apply beyond standard prescribing standards.

Hair loss

Hair loss treatment follows standard federal prescribing rules in Louisiana. No additional state restrictions apply.

ED (erectile dysfunction)

ED treatment follows standard federal prescribing rules in Louisiana. No additional state restrictions apply.

Peptides

Peptide therapy follows standard federal rules in Louisiana. Controlled peptides are subject to the in-person requirement under R.S. 40:1223.4. Non-controlled peptides have fewer restrictions. The Board of Pharmacy's compounding enforcement may affect peptide supply chains.